What Desmopressin is
Desmopressin is a vasopressin analog with stronger focus on antidiuretic signaling in approved clinical contexts.
Desmopressin is grouped under Endogenous / Biology / Approved / Clinical on PeptideFactCheck because it is a clear example of a modified peptide analog becoming a regulated medicine.
The useful starting point is to separate the molecule itself from the internet story around it. It shows how a natural peptide signal can be engineered into a medicine.
Why people keep looking it up
People know desmopressin as a vasopressin analog for water-balance conditions.
Desmopressin focuses vasopressin-like activity toward antidiuretic signaling.
Desmopressin tends to stay in the conversation because it touches a familiar public theme: v2 receptor, water balance, and vasopressin analog. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Official labeling matters because water-balance effects can be serious.
Human clinical evidence and official labels support specific uses.
Mechanism follows vasopressin receptor biology.
Why this page carries the current tier: Approved peptide analog with official labeling.
The current seed trail for Desmopressin is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Water-balance effects can be clinically important and should be discussed through labeling.
FDA-approved desmopressin products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Desmopressin. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Desmopressin is CID 5311065. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 5311065
- Formula
- C46H64N14O12S2
- Molecular weight
- 1069.2
- InChIKey
- NFLWUMRGJYTJIN-PNIOQBSNSA-N
Matched synonyms include DESMOPRESSIN, 16679-58-6, Desmopresina, Desmopressine, Desmopressinum, 1-Deamino-8-D-arginine vasopressin, 1-Desamino-8-D-arginine vasopressin, ENR1LLB0FP.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Desmopressin returns 122 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Desmopressin returns 5744 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Desmopressin Acetate
- Generic names
- DESMOPRESSIN ACETATE
- Routes
- ORAL
- Application numbers
- ANDA077414
Indications and usage. INDICATIONS AND USAGE Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for thera...
Contraindications. CONTRAINDICATIONS Desmopressin acetate tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate tablets. Desmopressin acetate tablets are contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50mL/min). Desmopressin acetate is contraindicated in patients with hyponatremia...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.